Premium
The recombinant kringle domain of urokinase plasminogen activator inhibits VEGF165‐induced angiogenesis of HUVECs by suppressing VEGFR2 dimerization and subsequent signal transduction
Author(s) -
Kim Byeong Mo,
Lee DongHeon,
Choi Hyun Jin,
Lee KeeHo,
Kang Su Jin,
Joe Young Ae,
Hong YongKil,
Hong Sung Hee
Publication year - 2012
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1002/iub.604
Subject(s) - angiogenesis , kringle domain , chemistry , phosphorylation , signal transduction , microbiology and biotechnology , vascular endothelial growth factor , umbilical vein , plasminogen activator , urokinase , activator (genetics) , urokinase receptor , cancer research , in vitro , recombinant dna , biochemistry , biology , receptor , vegf receptors , endocrinology , genetics , gene
The recombinant kringle domain (UK1) of urokinase plasminogen activator was previously reported to exert antiangiogenic activity against Vascular Endothelial Growth Factor (VEGF)‐induced angiogenesis in both in vitro and in vivo models. In this study, we explored the molecular signaling mechanisms involved in the antiangiogenic activity of UK1 by examining VEGF signaling proteins. VEGF165 stimulates the phosphorylation of VEGF signaling molecules, and pretreatment with UK1 blocked VEGF‐induced signal transduction associated with proliferation, survival, and migration. UK1 also suppressed VEGF165‐induced activation of MMP‐2. Moreover, UK1 suppressed the phosphorylation and activation of VEGFR2 in VEGF‐stimulated human umbilical cord vein endothelial cells (HUVECs) by blocking the dimerization of VEGFR2. Overall, our findings suggest that UK1 inhibits VEGF‐induced proliferation, migration, and matrix metalloproteinase activity of HUVECs by suppressing VEGFR2 dimerization and subsequent angiogenic signals. © 2012 IUBMB IUBMB Life, 2012